A Multicenter National Phase II Open Study Coupled With Translational Assessment of Biomarkers Predictive of Response to Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Hepatocellular Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2011
At a glance
- Drugs Sunitinib (Primary)
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- Acronyms FIBROLAMELLAIRE
- 30 Nov 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 18 Jan 2011 Planned end date changed from Oct 2013 to Feb 2014 as reported by ClinicalTrials.gov.
- 11 Oct 2010 New trial record